Welcome to NexusFi: the best trading community on the planet, with over 150,000 members Sign Up Now for Free
Genuine reviews from real traders, not fake reviews from stealth vendors
Quality education from leading professional traders
We are a friendly, helpful, and positive community
We do not tolerate rude behavior, trolling, or vendors advertising in posts
We are here to help, just let us know what you need
You'll need to register in order to view the content of the threads and start contributing to our community. It's free for basic access, or support us by becoming an Elite Member -- see if you qualify for a discount below.
-- Big Mike, Site Administrator
(If you already have an account, login at the top of the page)
as we reach the peak and things seem getting better I starting to think about the second wave, at this time we just put everything on hold, covid included. But what is gonna happen when we return to normal? We have already seen that just a few people infected can infect a country...so I think this will not be over until we find a vaccine or virus mutate itself to something less letal.
In the meantime the planet say thanks...less pollution and animals are taking back their space. We all should quarantine ourself and give this planet at least a 30 days holiday every year from humans.
Trading: The one I'm creating in the present....Index Futures mini/micro, ZF
Posts: 2,311 since Nov 2011
Thanks Given: 7,341
Thanks Received: 4,518
16:05 [INCY] Plans to initiate a Phase 3 clinical trial of ruxolitinib (Jakafi) as a treatment for patients with COVID-19 associated cytokine storm
- Also intends to launch an Expanded Access Program in the United States to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib
- Incyte has an ample commercial and clinical supply of ruxolitinib in the U.S. and is increasing manufacturing efforts in response to the COVID-19 pandemic
- announced the Company is working with the U.S. Food and Drug Administration (FDA) to initiate a Phase 3 clinical trial (RUXCOVID) to evaluate the efficacy and safety of ruxolitinib (Jakafi) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm. The collaborative study will be sponsored by Incyte in the United States and Novartis outside of the United States.
Additionally, given the urgent nature of the COVID-19 pandemic, Incyte intends to initiate a separate open-label emergency Expanded Access Program (EAP) in the United States. The protocol will allow eligible patients with severe COVID-19 associated cytokine storm to receive ruxolitinib while it is being investigated for this indication.
“Our intent is to build on emerging evidence from independent studies to further establish the role ruxolitinib could play in balancing immune response to the infection and therefore potentially improving outcomes of patients with COVID-19 associated cytokine storm,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “We recognize the significant and urgent medical need of patients with severe COVID-19 infection, and we are working with the FDA in an effort to rapidly advance the RUXCOVID and EAP studies.”
Sources Trade The News . com
Ron
...My calamity is My providence, outwardly it is fire and vengeance, but inwardly it is light and mercy...
The steed of this Valley is pain; and if there be no pain this journey will never end.
Buy Low And Sell High (read left to right or right to left....lol)
I'm assuming that the shortage of medical masks if because the brain dead are disposing of the masks at the end of a shift rather than sterilizing them??
Trump Administration Expected to Recommend All Americans Wear Cloth Masks in Public
The expected change in position reflects concern over a worrisome rate of infection spread by people with no symptoms.
A rider donned a facial covering on the Los Angeles metro rail on Wednesday. That city’s mayor, Eric Garcetti, had urged its residents to wear homemade masks or even bandannas when food shopping or doing other essential errands.Credit...Mario Tama/Getty Images
The researchers emphasized that the primary benefit of mask wearing was to prevent infected people from spreading the virus by expelling infected droplets.
The most recent estimate from “the leading US authority on the COVID-19 pandemic” suggests that the US may see between 100,000 and 200,000 deaths from COVID-19, with the final tally likely to be somewhere in the middle.” This means that we are expecting around 150,000 US deaths caused by the virus, if the latest estimates hold up.
According to the National Center for Health Statistics, over 48,000 suicides occurred in the US in 2018. This equates to an annual rate of about 14 suicides per 100,000 people. As expected, suicides increase substantially during times of economic depression. For example, as a result of the 2008 recession there was an approximate 25% increase. Similarly, during a peak year of the Great Depression, in 1932, the rate rose to 17 suicides per 100,000 people.
Trading: The one I'm creating in the present....Index Futures mini/micro, ZF
Posts: 2,311 since Nov 2011
Thanks Given: 7,341
Thanks Received: 4,518
They are not. They reuse. Same face mask for days. Designed for single use, for example. Attempt to clean face shields for the next day, at their own peril, after 12 hour shifts where 4 to 5 die per shift. 8 to 10 per day.
They have been trained their entire career to toss out disposable protective equipment once used for safety reasons. Retraining of personnel is nontrivial especially now in this super high stress environment for medical professionals with over run hospitals, overworked staff, at every level, and lack of support from governmental agencies at all strata.
Hospitals that once did heart transplants, hip replacements etc etc now only treat COVID-19 patients.
We need to start recognizing the Heroes and not name call. These doctors, nurses, technicians, administrative, paramedics, EMTs, Pharma bench scientist are one and all in need of praise, prayers, love and support.
Ron
...My calamity is My providence, outwardly it is fire and vengeance, but inwardly it is light and mercy...
The steed of this Valley is pain; and if there be no pain this journey will never end.
Buy Low And Sell High (read left to right or right to left....lol)
Well Ron I agree they are doing a tough job. My "brain dead" was about the administrators - not front line.
Your post highlights the brain dead of the admin who endanger the front line.
1. Disposable single use masks are not what is needed to be effective.
2. Face shields are not effective the aerosol goes around them.
They should have:
1. respirators
2. googles not face shields
3. air sterilizing machines
4. not treat Coivd in the same facility at regular patients
5. be sprayed with a sterilizer upon leaving a quarantine treatment facility (such as a alcohol mist)
Brain dead are NHS director appearing on TV and wearing a mask upside down and inside out and telling people mask are dangerous (when misused)
Now because of bad practices they are out of mask and are using bandanas - so your anger should go to those brain dead who place the front-line in this dangerous, stupid situation and risk their lives perhaps killing these front-line workers, and turn them, the health care workers carriers.
As long as the public blindly accepts what authority says the health-care workers are in peril and will continue to be.
1:24 PM 4/3/2020
How We'll Beat COVID-19: "Everyone Should Wear A Mask!"
the most effective single step each of us can take right now to beat covid-19 is to start wearing a mask.
It’s cheap. It’s easy. And if we all do it, it will give us a HUGE advantage in the fight against this pandemic.
You don’t need a fancy mask. A simple DIY version will suffice.
Wearing one does the following:
greatly reduces the particles a sick person can spread
prevents you from touching your mouth and nose, by far the most common way we can get infected
substantially increases your odds of having a mild case, should you get infected
If we all wear masks: I protect you, and you protect me. It just makes so much sense.
) plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm. The collaborative study will be sponsored by Incyte in the United States and Novartis outside of the United States.
